Philippe Calais
Chairman at TRANSCODE THERAPEUTICS, INC.
Net worth: 109 $ as of 2024-03-30
Profile
Philippe P.
Calais founded Phileas Pharma, Inc. in 2019, where he is working as Chairman from 2019.
Dr. Calais also currently works at MatriSys Bioscience, Inc., as President, Chief Executive Officer & Director and TransCode Therapeutics, Inc., as Executive Chairman from 2024.
Dr. Calais also formerly worked at Ambrilia Biopharma, Inc., as President, Chief Executive Officer & Director from 2008 to 2009, Univalor, Inc., as President & Chief Executive Officer from 2011 to 2012, Isarna Therapeutics BV, as President & Chief Executive Officer from 2012 to 2018, CohBar, Inc., as Director from 2019 to 2020, Neurochem (International) Ltd., as President & Director from 2003 to 2007, Adhera Therapeutics, Inc., as Lead Independent Director from 2017 to 2018, Medpharmgene, Inc., as Director from 2011 to 2012, Autotelic, Inc., as Director from 2016 to 2018, Cite Des Biotechs De Laval, as Director from 2002 to 2012, Cognisense, as Director from 2010 to 2012, BELLUS Health, Inc., as President-Global Business from 2003 to 2007, Hoffmann-La Roche, Inc., as Head-Global Strategic Marketing Unit, and Servier Canada, Inc., as General Manager from 2000 to 2002.
Dr. Calais received his undergraduate degree from Université Pierre et Marie Curie and undergraduate degree and doctorate degree from Université François-Rabelais de Tours.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-12-12 | 159 ( 0.00% ) | 109 $ | 2024-03-30 |
Philippe Calais active positions
| Companies | Position | Start |
|---|---|---|
| TRANSCODE THERAPEUTICS, INC. | Chairman | 2021-02-17 |
| Phileas Pharma, Inc. | Founder | 2019-04-30 |
MatriSys Bioscience, Inc.
 MatriSys Bioscience, Inc. BiotechnologyHealth Technology MatriSys Bioscience, Inc. engages in the development of biologic therapeutics. It offers therapies for dermatology and skin care conditions including atopic dermatitis, rosacea, psoriasis, acne, and skin infections. The company was founded by Mark S. Wilson and Richard L. Gallo in 2015 and is headquartered in La Jolla, CA. | Chief Executive Officer | - |
Former positions of Philippe Calais
| Companies | Position | End |
|---|---|---|
| COHBAR, INC. | Chief Executive Officer | 2019-05-14 |
Autotelic, Inc.
 Autotelic, Inc. Pharmaceuticals: MajorHealth Technology Autotelic, Inc. manufactures therapeutics drugs. Its Therapeutic Drug Monitoring (TDM) device which allows PK guided dosing, reducing the toxicity from overmedication and increasing the efficacy from under-medication. The company was founded in 2013 and is headquartered in Costa Mesa, CA. | Director/Board Member | 2018-05-31 |
Isarna Therapeutics BV
 Isarna Therapeutics BV Financial ConglomeratesFinance Isarna Therapeutics BV is an investment holding Dutch company. The private company is based in Zevenbergen, Netherlands. | Chief Executive Officer | 2018-05-31 |
| ADHERA THERAPEUTICS, INC. | Director/Board Member | 2018-05-01 |
| Cognisense | Director/Board Member | 2012-01-31 |
Training of Philippe Calais
| Université François-Rabelais de Tours | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| COHBAR, INC. | Health Technology |
| TRANSCODE THERAPEUTICS, INC. | Health Technology |
| ADHERA THERAPEUTICS, INC. | Health Technology |
| Private companies | 14 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
| Université Pierre et Marie Curie | Consumer Services |
Neurochem (International) Ltd.
 Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | Commercial Services |
Servier Canada, Inc.
 Servier Canada, Inc. Pharmaceuticals: MajorHealth Technology Servier Canada, Inc. provides healthcare services. It manufactures pharmaceuticals for cardiology, diabetes, depression, venous disease and menopause. The company was founded in 1978 and is headquartered in Quebec, Canada. | Health Technology |
Univalor, Inc.
 Univalor, Inc. Miscellaneous Commercial ServicesCommercial Services Univalor, Inc. engages in the provision of research and development services. The company was founded on April 27, 2001 and is headquartered in Montréal, Canada. | Commercial Services |
Medpharmgene, Inc.
 Medpharmgene, Inc. Miscellaneous Commercial ServicesCommercial Services Medpharmgene, Inc. provides commercial physical research services. The private company is based in Montréal, Canada and was founded in 2001. | Commercial Services |
MatriSys Bioscience, Inc.
MatriSys Bioscience, Inc. BiotechnologyHealth Technology MatriSys Bioscience, Inc. engages in the development of biologic therapeutics. It offers therapies for dermatology and skin care conditions including atopic dermatitis, rosacea, psoriasis, acne, and skin infections. The company was founded by Mark S. Wilson and Richard L. Gallo in 2015 and is headquartered in La Jolla, CA. | Health Technology |
| Phileas Pharma, Inc. | |
Isarna Therapeutics BV
Isarna Therapeutics BV Financial ConglomeratesFinance Isarna Therapeutics BV is an investment holding Dutch company. The private company is based in Zevenbergen, Netherlands. | Finance |
| Cite Des Biotechs De Laval | |
| Cognisense | |
Autotelic, Inc.
Autotelic, Inc. Pharmaceuticals: MajorHealth Technology Autotelic, Inc. manufactures therapeutics drugs. Its Therapeutic Drug Monitoring (TDM) device which allows PK guided dosing, reducing the toxicity from overmedication and increasing the efficacy from under-medication. The company was founded in 2013 and is headquartered in Costa Mesa, CA. | Health Technology |
- Stock Market
- Insiders
- Philippe Calais